RxDoctor Payments Data

Ewa Blachowicz, NP

Nurse Practitioner · Orland Park, ILNPI 1861514408

Payments from drug & device makers

$7,134in general payments, 2019–2025

Across 251 payments — averaging $28.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Teleflex LLC$1K
  • Axonics, Inc.$735
  • Sumitomo Pharma America, Inc.$622
  • Astellas Pharma US Inc$345
  • Urovant Sciences Inc$309
  • plus $3K from 27 others

What the payments were for

  • Travel & lodging$1,44620%
  • Food & beverage$5,29174%
  • Education$3976%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,134 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$33,009
Medicare patients
254
Services billed
677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron102$83,627
MyrbetriqMirabegron57$49,734
ElmironPentosan Polysulfate Sodium21$25,718
Tamsulosin Hcl676$11,827
Bethanechol Chloride154$11,064
Methenamine Hippurate157$10,057
Finasteride406$6,818
Alfuzosin Hcl ErAlfuzosin Hcl242$5,817
Potassium Citrate ErPotassium Citrate56$5,418
Silodosin37$3,649
Testosterone19$3,320
Estradiol40$1,977
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst80$1,710
Solifenacin Succinate38$1,671
Oxybutynin Chloride ErOxybutynin Chloride74$1,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$622$83,627102 claims
Astellas Pharma US IncMyrbetriq$345$49,73457 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Orland Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →